Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 6 6. CME Accreditation Page - p. 7 7. Section I: Nuclear Medicine in the Diagnosis and Treatment of Neuroendocrine Neoplasms - p. 8 8. Nuclear Medicine Procedures in the Diagnosis of NET - p. 9 9. Single-Photon Emission Computed Tomography Tracers in the Diagnostics of Neuroendocrine Tumors - p. 17 10. 18F-Fluorodihydroxyphenylalanine in the Diagnosis of Neuroendocrine Tumors - p. 27 11. 68Ga-DOTA-peptides in the Diagnosis of NET - p. 33 12. Role of 18F-Fluorodeoxyglucose PET in the Study of Neuroendocrine Tumors - p. 37 13. Other PET Tracers for Neuroendocrine Tumors - p. 46 14. Preclinical Studies of SPECT and PET Tracers for NET - p. 50 15. Yttrium-Based Therapy for Neuroendocrine Tumors - p. 56 16. Section II: Theranostics of Neuroendocrine Neoplasms - p. 66 17. Patient Selection for Personalized Peptide Receptor Radionuclide Therapy Using Ga-68 Somatostatin Receptor PET/CT - p. 67 18. Theranostics with Ga-68 Somatostatin Receptor PET/CT - p. 72 19. Relevance of PET for Pretherapeutic Prediction of Doses in Peptide Receptor Radionuclide Therapy - p. 76 20. Index - p. 82
No hay muestra disponible
No hay ficha técnica disponible
Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 6 6. CME Accreditation Page - p. 7 7. Section I: Nuclear Medicine in the Diagnosis and Treatment of Neuroendocrine Neoplasms - p. 8 8. Nuclear Medicine Procedures in the Diagnosis of NET - p. 9 9. Single-Photon Emission Computed Tomography Tracers in the Diagnostics of Neuroendocrine Tumors - p. 17 10. 18F-Fluorodihydroxyphenylalanine in the Diagnosis of Neuroendocrine Tumors - p. 27 11. 68Ga-DOTA-peptides in the Diagnosis of NET - p. 33 12. Role of 18F-Fluorodeoxyglucose PET in the Study of Neuroendocrine Tumors - p. 37 13. Other PET Tracers for Neuroendocrine Tumors - p. 46 14. Preclinical Studies of SPECT and PET Tracers for NET - p. 50 15. Yttrium-Based Therapy for Neuroendocrine Tumors - p. 56 16. Section II: Theranostics of Neuroendocrine Neoplasms - p. 66 17. Patient Selection for Personalized Peptide Receptor Radionuclide Therapy Using Ga-68 Somatostatin Receptor PET/CT - p. 67 18. Theranostics with Ga-68 Somatostatin Receptor PET/CT - p. 72 19. Relevance of PET for Pretherapeutic Prediction of Doses in Peptide Receptor Radionuclide Therapy - p. 76 20. Index - p. 82
No hay muestra disponible
No hay ficha técnica disponible
